Market Overview

NuVasive Wins Regulatory Shonin Approval to Broaden Offering in Japan

Related NUVA
NuVasive Receives First Ever FDA 510(k) Clearance of Cervical Corpectomy Cage
Benzinga's Top Upgrades

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today the Japanese approval of the CoRoent Large Impacted (LI) and CoRoent Large Tapered (LT) titanium alloy implants. The implants are used in posterior spine fusion procedures and are NuVasive's first two interbody fusion cages to be approved in Japan. The approvals further the Company's ability to participate in the world's second largest spine market with certain cervical solutions and a comprehensive posterior product offering, which have already been cleared for use.

Posted-In: News


Related Articles (NUVA)

Get Benzinga's Newsletters